Kenvue Inc. (NYSE:KVUE) Shares Sold by JPMorgan Chase & Co.

JPMorgan Chase & Co. decreased its holdings in Kenvue Inc. (NYSE:KVUE - Free Report) by 24.2% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 22,314,306 shares of the company's stock after selling 7,138,646 shares during the period. JPMorgan Chase & Co. owned 1.16% of Kenvue worth $476,410,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently modified their holdings of the stock. State Street Corp grew its stake in Kenvue by 16.8% in the third quarter. State Street Corp now owns 127,213,940 shares of the company's stock worth $2,942,458,000 after purchasing an additional 18,283,473 shares in the last quarter. Boston Partners boosted its stake in Kenvue by 36.9% in the fourth quarter. Boston Partners now owns 23,595,963 shares of the company's stock valued at $503,145,000 after acquiring an additional 6,366,097 shares in the last quarter. Holocene Advisors LP grew its holdings in Kenvue by 75.5% in the third quarter. Holocene Advisors LP now owns 13,886,454 shares of the company's stock worth $321,194,000 after purchasing an additional 5,975,392 shares during the last quarter. Raymond James Financial Inc. acquired a new position in shares of Kenvue during the fourth quarter worth $98,926,000. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its holdings in shares of Kenvue by 30.2% during the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 9,992,933 shares of the company's stock valued at $231,137,000 after purchasing an additional 2,316,443 shares during the last quarter. Hedge funds and other institutional investors own 97.64% of the company's stock.

Analysts Set New Price Targets

A number of research firms have commented on KVUE. Barclays increased their price target on Kenvue from $21.00 to $23.00 and gave the company an "equal weight" rating in a research note on Thursday, March 27th. Royal Bank of Canada reiterated a "sector perform" rating and issued a $24.00 target price on shares of Kenvue in a research note on Monday, February 3rd. Canaccord Genuity Group upped their price target on shares of Kenvue from $24.00 to $29.00 and gave the company a "buy" rating in a research note on Wednesday, March 5th. Evercore ISI initiated coverage on shares of Kenvue in a report on Monday, March 24th. They issued an "in-line" rating and a $25.00 price target on the stock. Finally, Deutsche Bank Aktiengesellschaft lowered shares of Kenvue from a "buy" rating to a "hold" rating and cut their target price for the company from $25.00 to $24.00 in a report on Thursday, December 12th. One research analyst has rated the stock with a sell rating, eight have given a hold rating and five have assigned a buy rating to the stock. According to MarketBeat.com, the stock has an average rating of "Hold" and an average price target of $24.00.

Kenvue Stock Performance

Shares of NYSE:KVUE traded down $0.10 during midday trading on Thursday, hitting $23.77. The stock had a trading volume of 3,188,772 shares, compared to its average volume of 14,697,462. The company has a current ratio of 1.00, a quick ratio of 0.69 and a debt-to-equity ratio of 0.66. The stock has a 50 day moving average price of $22.50 and a two-hundred day moving average price of $22.47. Kenvue Inc. has a 1 year low of $17.67 and a 1 year high of $24.46. The company has a market capitalization of $45.43 billion, a PE ratio of 44.85, a P/E/G ratio of 2.62 and a beta of 1.25.

Kenvue (NYSE:KVUE - Get Free Report) last announced its quarterly earnings results on Thursday, February 6th. The company reported $0.26 earnings per share for the quarter, meeting analysts' consensus estimates of $0.26. Kenvue had a return on equity of 20.97% and a net margin of 6.66%. As a group, equities analysts predict that Kenvue Inc. will post 1.14 earnings per share for the current fiscal year.

Kenvue Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Wednesday, February 26th. Shareholders of record on Wednesday, February 12th were paid a dividend of $0.205 per share. This represents a $0.82 dividend on an annualized basis and a dividend yield of 3.45%. The ex-dividend date was Wednesday, February 12th. Kenvue's dividend payout ratio is presently 154.72%.

Kenvue Company Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.